# Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

> **NCT00939510** · PHASE1,PHASE2 · COMPLETED · sponsor: **Robert Dreicer MD** · enrollment: 32 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** lenalidomide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00939510
- **Lead sponsor:** Robert Dreicer MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-10
- **Final completion:** 2012-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939510, "Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00939510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*